A new type of pericyte called Peri2 is linked to scar tissue formation in the lungs of people with pulmonary fibrosis (PF), according to a study. Pericytes are cells that surround blood vessels. A gene called FOXF1 was also shown to help control whether these cells stay healthy or…
News
According to its U.S. developer, the first of two global clinical trials designed to test Haduvio (nalbuphine extended-release) — a potential treatment for chronic cough due to idiopathic pulmonary fibrosis (IPF) — is now underway, with the second expected to launch later this year. The initial Phase 3 trial,…
The inhaled therapy MNKD-201 was tolerated well in people with idiopathic pulmonary fibrosis (IPF) in a Phase 1 clinical trial, and a Phase 2 study to further test it is underway, the treatment’s developer said. The Phase 2 trial, INFLO-2 (NCT07679893), aims to enroll more than 200 adults…
An international clinical trial testing LTI-03, Rein Therapeutics’ inhaled treatment candidate for idiopathic pulmonary fibrosis (IPF), is now recruiting participants at sites in five countries. The Phase 2 trial, dubbed RENEW (NCT06968845), aims to enroll approximately 120 people with IPF, ages 40 and older. Eligible participants will…
The oral therapy Jascayd (nerandomilast) has been approved in the European Union for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The marketing authorization from the European Commission follows a positive recommendation from a regulatory committee and marks the first new IPF therapy approved…
The Pulmonary Fibrosis Foundation (PFF), an advocacy group dedicated to advancing care for people with pulmonary fibrosis, has added two new members to its board of directors. Both new board members are physicians with extensive experience caring for people with pulmonary fibrosis, which causes scarring in the lungs,…
Celea Therapeutics received $180 million in financing to develop deupirfenidone (LYT-100), an investigational therapy that the company says has the potential to serve as a new standard of care for people with idiopathic pulmonary fibrosis (IPF). The funding will support the planned launch of SURPASS-IPF (NCT07284602), a…
Problems in a cell death process called ferroptosis may contribute to the formation of scar tissue in the lungs in idiopathic pulmonary fibrosis (IPF), a study suggests. In ferroptosis, which is an iron-dependent process, reactive oxygen molecules damage cell membranes, leading to cell death. In the study, the researchers described…
GRI Bio‘s experimental oral therapy GRI-0621 (tazarotene) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF), a disease with no known cause that’s marked by inflammation and fibrosis, or scarring, that damages the lungs. The developer…
Familial pulmonary fibrosis (FPF) makes up a notable portion of all cases of interstitial lung disease, disorders marked by scarring in the lungs, and tends to appear differently from non-familial versions of the disease, a large, multicenter study has found. While survival outcomes were similar between the two groups,…
